Goldway Holdings: The company's controlling shareholder and actual controller Zheng Licheng, Yang Wei, Zhao Guoquan, Zheng Xiaojun, and Ye Jianyang, as well as the company's shareholders Quzhou Tongwo Investment Management (Limited Partnership) and Quzhou Chengwei Enterprise Management Co., Ltd., voluntarily promised not to reduce their holdings in the company's shares in any way from the date of the lifting of the restricted shares of the company's initial public offering until June 17, 2025, based on the shares they hold. Amoy Diagnostics: The company has signed a companion diagnostic cooperation agreement with LES LABORATOIRES SERVIER (referred to as "Servier"), for the companion diagnostic product of the second-generation sequencing (NGS) platform developed by the company, which is used to detect Isocitrate dehydrogenase (IDH) 1 and 2 gene mutations. The companion diagnostic product will be used for Servier's research new drug Vorasidenib, which is a dual inhibitor of mutated isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2), and is expected to be used for the treatment of diffuse glioma (LGG) carrying IDH mutations in Chinese patients after it is approved.